NCT06823700招募中不适用
A Prospective, Multicenter, Single Arm Study to Evaluate the Safety and Effectiveness of Shenqi Transcatheter Mitral Valve Clips Delivery System and Steerable Guide Catheters in Patients with Functional Mitral Regurgitation
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 34
- 试验地点
- 2
- 主要终点
- Number of patients with composite measures- All-cause death and recurrent hospitalizations due to heart failure
研究概览
简要总结
The investigation objective of this study is to evaluate the safety and effectiveness of the Transcatheter Mitral Valve Clip Delivery System and Steerable Guide Catheter in the population of FMR patients and the accessories devices when used in conjunction with the Transcatheter Mitral Valve Clip Delivery System and Steerable Guide Catheter.
详细描述
The primary objective is to verify the safety and effectiveness of the Transcatheter Mitral Valve Clip Delivery System and Steerable Guide Catheter produced by Shanghai Shenqi Medical Technology Co., Ltd. In the treatment of patients with moderate-severe (3 +) or severe (4 +) FMR whose symptoms and MR severity persist despite maximally tolerated GDMT as determined by a multidisciplinary heart team experienced in the evaluation and treatment of heart failure and mitral valve disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant who has provided written informed consent for the investigation.
- •Age ≥18 years.
- •Patients diagnosed with FMR.
- •MR severity is (functional) ≥3+ as determined by transthoracic echocardiography (TTE).
- •LVEF ≥20% to ≤60%.
- •Symptom status: NYHA functional class II to IV despite a stable maximally tolerated GDMT regimen as per guidelines.
- •According to the judgment of local cardiology team, subjects have undergone adequate treatment for at least 30 days (preferably 90 days) based on the criteria recommended in the heart failure guidelines.
- •Subject fulfils FMR anatomy selection criteria.
- •According to the judgment of the local Cardiovascular medical-surgery team, subjects who have high or prohibitive risk for open heart surgery.
- •Left ventricular end-systolic diameter (LVESD)≤70mm.
- •The MR beam mainly originates from the A2/P2 area.
- •Mitral valve coaptation depth≤11mm, coaptation height≥2mm, effective length of anterior and posterior leaflets>10mm.
- •Mitral valve effective orifice area (EOA) ≥ 4.0cm
- •No obvious calcification of main grasp mitral valve leaflets.
- •Patient anatomy allows atrial septum approach.
排除标准
- •Life expectancy <1 year due to non-cardiac conditions or heart failure deemed suitable for palliative treatment.
- •Hypotension (systolic pressure <90 mm Hg) or requirement for inotropic support or mechanical hemodynamic support.
- •UNOS status 1 heart transplantation or prior orthotopic heart transplantation.
- •Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology.
- •Fixed pulmonary artery systolic pressure >70 mm Hg.
- •Physical evidence of right-sided congestive heart failure with echocardiographic evidence of moderate or severe right ventricular dysfunction.
- •Mitral valve anatomy which may preclude proper device treatment.
- •Mitral valve area < 4.0 cm2 (if new device therapy may further decrease the mitral orifice area).
- •Any prior mitral valve surgery or transcatheter mitral valve procedure.
- •Stroke or transient ischemic event within 30 days before enrolment.
- •Modified Rankin ≥ Scale 4 disability.
- •Severe symptomatic carotid stenosis (>70% by ultrasound).
- •Need for emergent or urgent intervention for any reason or any planned cardiac intervention within the next 12 months.
- •Implant or revision of any rhythm management device (CRT or CRT-D) or implantable cardioverter-defibrillator within 1 month before enrolment.
- •Untreated clinically significant coronary artery disease requiring revascularization.
- •Any percutaneous cardiovascular intervention, cardiovascular intervention, or carotid intervention within 30 days
- •Tricuspid valve disease requiring intervention or severe or more tricuspid regurgitation.
- •Aortic valve disease requiring intervention or any concomitant treatment.
- •Need for any cardiovascular intervention (other than for MV disease).
- •Echocardiographic evidence of intracardiac mass, thrombus, or vegetation.
- •Active endocarditis.
- •Active infections requiring current antibiotic therapy.
- •Subjects in whom transoesophageal echocardiography is contraindicated or high risk.
- •Any condition making it unlikely the patient will be able to complete all protocol procedures (including compliance with guideline directed medical therapy) and follow-up visits.
- •Patient unable or unwilling to provide written, informed consent before study enrolment.
- •Pregnant woman or woman planning to become pregnant.
- •Patients with severe liver, renal or pulmonary disease, which in investigator opinion may have an impact on patient safety.
- •Clinically significant lab abnormalities which in investigator opinion may have an impact on patient safety.
结局指标
主要结局
Number of patients with composite measures- All-cause death and recurrent hospitalizations due to heart failure
时间窗: 12 months
A composite of all-cause death and recurrent hospitalizations due to heart failure
次要结局
- Improvement by ≥ 50m in 6-minute walk distance from baseline(12 months)
- Improvement in left ventricular end-diastolic volume (LVEDV) from baseline(12 months)
- Technical success rate(immediately after intervention)
- The rate of New York Heart Association (NYHA) heart function class I or II(On the day of discharge, 30 days, 6 months, and 12 months)
- Change from baseline to discharge in MR severity assessed by echocardiography.(On the day of discharge)
- Device success rate(30 days)
- Procedural success rate(30 days)
- Improvement in quality of life from baseline(12 months)
- Rate of MR 2+ or less than 2+(30 days, 6 months, and 12 months)
- Incidence of all-cause mortality(30 days, 6 months, and 12 months)
- Rate of hospitalization for heart failure(30 days, 6 months, and 12 months)
- Cardiovascular-related mortality(30 days, 6 months, and 12 months)
- Incidence of major adverse events(30 days and 12 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Instylla Hydrogel Embolic System First In Human Study For Patients Requiring Vascular Embolization Alone or in the Pre-operative Setting for Treatment of Malignant and Benign Hypervascular Tumors, and Select Non-Traumatic End-Organ InfarctPatients Requiring Vascular Embolization Alone for Treatment of Malignant TumorsPatients Requiring Vascular Embolization in the Pre-operative Setting for Treatment of Malignant TumorsPatients Requiring Vascular Embolization Alone for Treatment of Benign Hypervascular TumorsPatients Requiring Vascular Embolization in the Pre-operative Setting for Treatment of Benign Hypervascular TumorsPatients Requiring Vascular Embolization for Select Non-Traumatic End-Organ InfarctCancer - LiverCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemCancer - BoneCancer - KidneyACTRN12619000536167Instylla Inc8
尚未招募
4 期
The aim is to evaluate the safety and efficacy of MeRes100™ Sirolimus Eluting BioResorbable Vascular Scaffold in coronary artery disease patients.It enhances coronary luminal diameter in symptomatic ischemic heart disease, addressing de novo lesions in native coronary arteries.CTRI/2024/02/062438Meril Diagnostics Private Limited
尚未招募
4 期
A study of Romiplostim Powder for Injection in patientsCTRI/2021/08/035609Intas Pharmaceuticals Limited
撤回
3 期
A Prospective, Multi-Center, Single Arm Study of the Conor Cobalt Chromium Reservoir Based Stent (Nevo) with Sirolimus Elution in Native Coronary Artery Lesions (CP-07 protocol)atherosclerosisNL-OMON32462Conor Medsystems, LLC (maakt deel uit van Johnson & Johnson); contact persoon Emily Hergenreter40
进行中（未招募）
1 期
A multicenter, single-arm prospective study to determine safety and efficacy of GLE/PIB 8-week treatment in adults and adolescents acutely infected with hepatitis C virusEUCTR2020-005777-27-DEAbbVie Deutschland GmbH & Co. KG283